GlassScriptPhysician profile
Alex Dejesus
NPI 1013986629
$68,122.47
in general payments reported to CMS, 2019-2025
31 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $19K · 2021: $2,396.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $42,858.83 | 2019-2021 | |
| Abbvie INC. | $17,165.15 | 2019-2021 | |
| Janssen Biotech, INC. | $4,027.66 | 2019-2021 | |
| Horizon Therapeutics Plc | $1,011.03 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $464.71 | 2019-2021 | |
| Ucb, INC. | $316.56 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $310.59 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $259.41 | 2019-2021 | |
| Amgen INC. | $244.88 | 2019-2021 | |
| Genzyme Corporation | $183.53 | 2019-2021 | |
| Glaxosmithkline, LLC. | $179.52 | 2019-2021 | |
| Genentech USA, INC. | $164.85 | 2019 | |
| Radius Health, INC. | $143.81 | 2019 | |
| Pfizer INC. | $128.79 | 2019-2021 | |
| Antares Pharma, INC. | $127.82 | 2019-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $125.22 | 2019-2021 | |
| Pacira Therapeutics, INC. | $108.21 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $97.78 | 2019-2021 | |
| Mallinckrodt Enterprises LLC | $51.02 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $39.33 | 2021 | |
| Medexus Pharma, INC. | $32.68 | 2019 | |
| Sanofi-Aventis U.S. LLC | $24.96 | 2019 | |
| Organon LLC | $15.28 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.15 | 2020 | |
| Bioventus LLC | $13.57 | 2019 | |
| Ferring Pharmaceuticals INC. | $12.13 | 2020 |
5 companies reported research payments only; those appear in the research section below.
Research and ownership
$30,232.10 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alex Dejesus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.